Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

SC-N132, Feasibility of Ex Vivo Drug Sensitivity and Genomic Screening for Pediatric Patients with Relapsed and Refractory Acute Leukemias

SC-N132

Condition: Leukemia & Lymphoma
Phase: N/A

What is the goal of the study?

The primary objective is to determine the feasibility of identifying patient specific therapeutic regimens based on the pairing of ex vivo drug sensitivity testing and genomic sequencing in pediatric patients with relapsed/refractory leukemias within 45 days.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Katherine Tarlock
Study Team Member: HemOnc CRAs, HemOncCRAs@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.